Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

Respiratory Research

Tim Overend³  Donald Banerji¹  Yimeng Lu¹  Rachael Horton³  Carmen Martin³  Kazuto Hirata²  Jan A van Noord⁵  Gary T Ferguson⁶  Anthony D'Urzo⁴ 

[1] Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;Osaka City University, Abeno-ku, Osaka, Japan;Novartis Horsham Research Centre, West Sussex, UK;Department of Family and Community Medicine (DFCM), University of Toronto, Ontario, Canada;Atrium Medisch Centrum, Heerlen, The Netherlands;Pulmonary Research Institute of Southeast Michigan, Livonia, Michigan, USA

关键词: exacerbations;    quality of life;    dyspnoea;    LAMA;    COPD;    once-daily;    NVA237;   

Others  :  796766
DOI  :  10.1186/1465-9921-12-156

 received in 2011-09-16, accepted in 2011-12-07,  发布年份 2011

【 摘 要 】

Background

NVA237 is a once-daily dry-powder formulation of the long-acting muscarinic antagonist glycopyrronium bromide in development for the treatment of chronic obstructive pulmonary disease (COPD). The glycopyrronium bromide in COPD airways clinical study 1 (GLOW1) evaluated the efficacy, safety and tolerability of NVA237 in patients with moderate-to-severe COPD.

Methods

Patients with COPD with a smoking history of ≥ 10 pack-years, post-bronchodilator forced expiratory volume in 1 second (FEV₁) < 80% and ≥ 30% predicted normal and FEV₁/forced vital capacity < 0.70 were enrolled. Patients were randomized to double-blind treatment with NVA237 50 μg once daily or placebo for 26 weeks with inhaled/intranasal corticosteroids or H₁ antagonists permitted in patients stabilized on them prior to study entry. The primary outcome measure was trough FEV₁ at Week 12.

Results

A total of 822 patients were randomized to NVA237 (n = 552) or placebo (n = 270). Least squares mean (± standard error) trough FEV₁ at Week 12 was significantly higher in patients receiving NVA237 (1.408 ± 0.0105 L), versus placebo (1.301 ± 0.0137 L; treatment difference 108 ± 14.8 mL, p < 0.001). Significant improvements in trough FEV₁ were apparent at the end of Day 1 and sustained through Week 26. FEV₁ was significantly improved in the NVA237 group versus placebo throughout the 24-hour periods on Day 1 and at Weeks 12 and 26, and at all other visits and timepoints. Transition dyspnoea index focal scores and St. George's Respiratory Questionnaire scores were significantly improved with NVA237 versus placebo at Week 26, with treatment differences of 1.04 (p < 0.001) and-2.81 (p = 0.004), respectively. NVA237 significantly reduced the risk of first moderate/severe COPD exacerbation by 31% (p = 0.023) and use of rescue medication by 0.46 puffs per day (p = 0.005), versus placebo. NVA237 was well tolerated and had an acceptable safety profile, with a low frequency of cardiac and typical antimuscarinic adverse effects.

Conclusions

Once-daily NVA237 was safe and well tolerated and provided rapid, sustained improvements in lung function, improvements in dyspnoea, and health-related quality of life, and reduced the risk of exacerbations and the use of rescue medication.

Trial registration

ClinicalTrials.gov: NCT01005901

【 授权许可】

   
2011 D'Urzo et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]GOLD: Global strategy for diagnosis, management and prevention of COPD. [http://www.goldcopd.com/] webcite 2010.
• [2]Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, Carrozzi L: Definition, epidemiology and natural history of COPD. Eur Respir J 2007, 30:993-1013.
• [3]Kesten S, Celli B, Decramer M, Leimer I, Tashkin D: Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis 2009, 4:397-409.
• [4]Casaburi R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr: The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000, 118:1294-1302.
• [5]Beeh KM, Welte T, Buhl R: Anticholinergics in the treatment of chronic obstructive pulmonary disease. Respiration 2002, 69:372-379.
• [6]Fogarty C, Hattersley H, Di SL, Drollmann A: Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2011, 105:337-342.
• [7]Verkindre C, Fukuchi Y, Flemale A, Takeda A, Overend T, Prasad N, Dolker M: Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2010, 104:1482-1489.
• [8]Vogelmeier C, Verkindre C, Cheung D, Galdiz JB, Guclu SZ, Spangenthal S, Overend T, Henley M, Mizutani G, Zeldin RK: Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther 2010, 23:438-444.
• [9]GOLD: Global Strategy for the diagnosis, management and prevention of COPD. [http://www.goldcopd.com/] webcite 2008.
• [10]World Medical Association: Declaration of Helsinki-ethical principals for medical research involving human subjects. 2008.
• [11]Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
• [12]Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GK, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106:196-204.
• [13]Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA: Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:1418-1422.
• [14]Witek TJ Jr, Mahler DA: Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003, 21:267-272.
• [15]Jones P, Lareau S, Mahler DA: Measuring the effects of COPD on the patient. Respir Med 2005, 99(Suppl B):S11-S18.
• [16]Rice KL, Kunisaki KM, Niewoehner DE: Role of tiotropium in the treatment of COPD. Int J Chron Obstruct Pulmon Dis 2007, 2:95-105.
• [17]Haddad EB, Patel H, Keeling JE, Yacoub MH, Barnes PJ, Belvisi MG: Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br J Pharmacol 1999, 127:413-420.
• [18]Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138.
• [19]Seemungal TA, Hurst JR, Wedzicha JA: Exacerbation rate, health status and mortality in COPD--a review of potential interventions. Int J Chron Obstruct Pulmon Dis 2009, 4:203-223.
• [20]Beeh KM, Beier J, Buhl R, Stark-Lorenzen P, Gerken F, Metzdorf N: Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities. Pneumologie 2006, 60:341-346.
• [21]Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002, 19:217-224.
• [22]Chan CK, Maltais F, Sigouin C, Haddon JM, Ford GT: A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J 2007, 14:465-472.
• [23]Freeman D, Lee A, Price D: Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study. Respir Res 2007, 8:45. BioMed Central Full Text
• [24]Johansson G, Lindberg A, Romberg K, Nordstrom L, Gerken F, Roquet A: Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Respir J 2008, 17:169-175.
• [25]Moita J, Barbara C, Cardoso J, Costa R, Sousa M, Ruiz J, Santos ML: Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm Pharmacol Ther 2008, 21:146-151.
• [26]Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, Cassino C, Kesten S: Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005, 143:317-326.
• [27]Verkindre C, Bart F, Aguilaniu B, Fortin F, Guerin JC, Le MC, Iacono P, Huchon G: The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006, 73:420-427.
• [28]Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S: Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003, 58:399-404.
• [29]Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
• [30]Tonnel AB, Perez T, Grosbois JM, Verkindre C, Bravo ML, Brun M: Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis 2008, 3:301-310.
• [31]Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM, POET-COPD Investigators: Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011, 364:1093-1103.
• [32]van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ: A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000, 55:289-284.
• [33]Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ: Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006, 148:565-578.
• [34]Cooper N, Walker I, Knowles I: NVA237 and tiotropium bromide demonstrate similar efficacy in an anesthetized rabbit model of methacholine-induced bronchoconstriction. NVA237 demonstrates a reduced systemic pharmacological effect on cardiovascular parameters [abstract]. Proc Am Thoracic Soc 2006, 3:A117.
• [35]Trifilieff Cope N, Bohacek B, Mazzoni L, Collingwood S: The inhaled antimuscarinic receptor antagonist, NVA237 (glycopyrrolate), has a favorable side-effect profile in a Brown Norway rat lung function model when compared with tiotropium [abstract]. Chest 2007, 132:530a.
• [36]Diaz O, Villafranca C, Ghezzo H, Borzone G, Leiva A, Milic-Emil J, Lisboa C: Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J 2000, 16:269-275.
• [37]Belman MJ, Botnick WC, Shin JW: Inhaled bronchodilators reduce dynamic hyperinflation during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996, 153:967-975.